Allogeneic peripheral blood stem cell transplantation (PBSCT) from HLA-identical sibling donors in children with hematological diseases: a single center pilot study

Bone Marrow Transplantation
A I BenitoM A Díaz

Abstract

Between February 1995 and July 1999 25 pediatric patients (8 months to 14 years old) underwent peripheral blood stem cell transplantation (PBSCT) from an HLA-identical sibling donor. Diagnoses included ALL (17), non-ALL (6), and non-malignant disease (2). GVHD prophylaxis consisted of cyclosporine plus methotrexate (15), only cyclosporine (8), cyclosporine plus prednisone (1), or nothing (1). All donors (6 months to 41 years old) received G-CSF at 10 microg/kg/day subcutaneously for 4-5 days and on day 5 underwent large volume leukapheresis. Median number of CD34(+) and CD3(+) cells collected and infused was 6.9 x 10(6) (range 2.5-32.8) and 4.5 x 10(8) (0.5-22.1) per kg of recipient body weight respectively. Median time to achieve ANC >0.5 x 10(9)/l and platelets >20 x 10(9)/l was 10 and 12 days, respectively. Acute GVHD grade > or =II developed in 10 of 24 evaluable patients (42%). Probability of acute GVHD was 62%. Median time to discharge was 25 days (range 14-52). Among 20 evaluable patients, five (25%) developed chronic GVHD at day 100. Probability of chronic GVHD was 29% after 1 year post PBSC. At a median follow-up of 558 (9-2071) days, overall survival for the whole group is 68%. Probabilities of event-free survival, ov...Continue Reading

References

Apr 17, 1975·The New England Journal of Medicine·E ThomasC D Buckner
Apr 24, 1975·The New England Journal of Medicine·E D ThomasC D Buckner
Aug 1, 1980·The American Journal of Medicine·H M ShulmanE D Thomas
Jun 1, 1996·International Journal of Hematology·M KuroiwaY Niho
Jan 22, 1998·Medical and Pediatric Oncology·C K LiH Lai
Mar 10, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R A BrownJ F DiPersio
Jun 18, 1999·Bone Marrow Transplantation·R LeBlancG Cantin
Jul 8, 2000·Pediatric Dermatology·A TorreloA Zambrano
Mar 10, 2001·Transfusion·U PlatzbeckerK Hölig
Mar 10, 2001·Transfusion·J de La RubiaM A Sanz

❮ Previous
Next ❯

Citations

Feb 28, 2008·Current Opinion in Oncology·Ebru Koca, Richard E Champlin
Jan 27, 2012·Seminars in Dialysis·Stuart L Goldstein
Mar 24, 2010·Pediatric Clinics of North America·Kristin BairdKirk R Schultz

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.